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Abstract
Background: It has been reported that human FOXP3
+ CD4 Tregs express GARP-anchored surface latency-associated
peptide (LAP) after activation, based on the use of an anti-human LAP mAb. Murine CD4 Foxp3
+ Tregs have also been
reported to express surface LAP, but these studies have been hampered by the lack of suitable anti-mouse LAP mAbs.
Methodology/Principal Findings: We generated anti-mouse LAP mAbs by immunizing TGF-b
2/2 animals with a mouse
Tgfb1-transduced P3U1 cell line. Using these antibodies, we demonstrated that murine Foxp3
+ CD4 Tregs express LAP on
their surface. In addition, retroviral transduction of Foxp3 into mouse CD4
+CD25
2 T cells induced surface LAP expression.
We then examined surface LAP expression after treating CD4
+CD25
2 T cells with TGF-b and found that TGF-b induced
surface LAP not only on T cells that became Foxp3
+ but also on T cells that remained Foxp3
2 after TGF-b treatment. GARP
expression correlated with the surface LAP expression, suggesting that surface LAP is GARP-anchored also in murine T cells.
Conclusions/Significance: Unlike human CD4 T cells, surface LAP expression on mouse CD4 T cells is controlled by Foxp3
and TGF-b. Our newly described anti-mouse LAP mAbs will provide a useful tool for the investigation and functional analysis
of T cells that express LAP on their surface.
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Introduction
TGF-b controls immune responses by multiple mechanisms
including the suppression of Th1 and cytotoxic lymphocytes, and
the induction of Th17 cells depending on the context [1]. TGF-b is
first synthesized as pro-TGF-b and is then intracellularly processed
by furin proprotein convertase to form a latent TGF-b complex
which consists of non-covalently associated dimmers of the N-
terminal region of pro-TGF-b (latency-associated peptide, LAP)
and of the C-terminal region of pro-TGF-b (mature TGF-b) [2].
Expression of pro-TGF-b, LAP, latent TGF-b and/or mature
TGF-b (hereafter referred as LAP/TGF-b) on mouse CD4 T cells
was first reported in 2001 by Nakamura et al. [3]. They proposed
that CD4
+CD25
+ regulatory T cells (Tregs) mediated their
suppressive function by presenting active TGF-b to effector cells
in a cell-cell contact manner. They used a polyclonal chicken anti-
TGF-b antibody and a monoclonal anti-human LAP mAb (clone
27232)forFACSstaining ofmouseCD4T cells.Ourlaboratoryhas
also reported the presence of surface LAP
+ on mouse T cells using a
polyclonal goat anti-human LAP antibody [4,5]. However, use of a
polyclonal antibody is problematical due to the inherent variance
between different polyclonal preparations. The anti-LAP mAb
(clone 27232) used by Nakamura, et al., was raised against
recombinant human LAP (R&D Systems). Although Nakamura et
al. used this antibody to stain mouse CD4 T cells [3], in our hands,
we did not find that this anti-human LAP mAb cross-reacted with
mouse LAP. Thus, although clone 27232 stained human TGFB1-
transduced cells [6], it did not stain mouse Tgfb1-tranduced cells at
all (Figure S1). To overcome these problems, a fully characterized
anti-mouse LAP mAb would be required for staining mouse T cells.
Recently, by using the anti-human LAP mAb 27232 [7,8], it
was reported that human FOXP3
+ Tregs express surface LAP
after activation and that the surface LAP is anchored by GARP/
LRRC32 [8,9].
We raised anti-mouse LAP mAbs by immunizing TGF-b
2/2 mice
with mouse Tgfb1-transduced cells, and used them to stain mouse
CD4 T cells. We found that the majority of mouse Foxp3
+ CD4 T
cells expressed surface LAP after activation. Surface LAP was induced
by Foxp3-transduction into mouse CD4
+CD25
2 Tc e l l sa n db y
addition of TGF-b to mouse CD4
+CD25
- T cell cultures. In contrast
to human T cells [8], TGF-b induced surface LAP not only on T cells
that converted to Foxp3
+ but also on T cells in which Foxp3 was not
expressed. GARP expression correlated with the surface LAP
expression suggesting that surface LAP is anchored by GARP.
Results
Generation of anti-mouse LAP mAbs
We used mouse Tgfb1-transduced P3U1 (P3U1-muTGF-b cells)
cells as an immunogen. We have recently shown that human
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15523TGFB1-transduced P3U1 (P3U1-huTGF-b) cells express LAP/
TGF-b on the surface [6]. Surface expression of murine LAP was
also expected on P3U1-muTGF-b cells since we found that anti-
TGF-b (clone 9016) surface stained P3U1-muTGF-b cells as well
as P3U1-huTGF-b cells (Figure S1). We elected to immunize
TGF-b-deficient mice. TGF-b
2/2 mice manifest an autoimmune
syndrome and die at 3–4 wks after birth [10,11]. We attempted to
prolong their life by injecting galectin-1, which has been reported
to suppress other autoimmune diseases [12], starting at day 7 of
birth. P3U1-muTGF-b cells were injected i.p. every other day 5
times beginning at day 8 after birth, and spleen cells were taken at
day 22 after birth and fused with P3U1 myeloma cells. The
hybridoma cells were grown in hypoxanthine-aminopterin-thymi-
dine (HAT)-supplemented methylcellulose medium. Approximate-
ly 2,800 clones were picked from the plates, and transferred to
hypoxanthine-thymidine (HT)-supplemented DMEM in 96-well
plates. The culture supernatants were screened by surface staining
of P3U1-muTGF-b cells by FACS. Thirty-six positive clones were
selected and recovered (TW7 series) (Figure S2). Of the 36 clones,
32 clones were IgG and 4 clones were IgM. To check their
specificity, we tested the ability of the antibodies to immunopre-
cipitate Flag-tagged mouse LAP (Flag-mLAP) produced by
retrovirally Flag-mLAP-transduced P3U1 cells. Of the 32 IgG
clones, 26 clones, including TW7-16B4 and TW7-20B9, immu-
noprecipitated Flag-mLAP (Figure S3, underlined) and thus were
true anti-mouse LAP mAbs. Several clones, including TW7-
28G11, did not immunoprecipitate Flag-mLAP (Figure S3). TW7-
28G11, however, stained human latent TGF-b-coated beads, but
not human LAP- or human active TGF-b-coated beads (Figure
S4A). TW7-28G11 immunoprecipiated Flag-mLAP only when
active TGF-b was exogenously added to Flag-mLAP solution
(Figure S4B), and immunoprecipiated pro-TGF-b and latent
TGF-b from the culture supernatant of P3U1-muTGF-b cells
(Figure S5A). These results indicate that TW7-28G11 is a
conformation specific anti-mouse/human latent TGF-b/pro-
TGF-b mAb which recognize LAP and TGF-b in combination.
The specificity of some clones, including TW7-16B4, TW7-20B9
and TW7-28G11, were further confirmed by testing their ability to
detect mouse pro-TGF-b and/or LAP by Western blot (Figure
S5B), and by their ability to immunoprecipiate pro-TGF-b and
latent TGF-b from culture supernatant of P3U1-muTGF-b cells
(Figure S5A).
Surface LAP expression on mouse Foxp3
+ CD4 T cells
It has been reported that human FOXP3 Tregs express surface
LAP after activation [7,8] by a GARP-mediated anchoring
mechanism [8,9]. We tested our anti-LAP/TGF-b mAbs for their
ability to stain pre-activated mouse CD4 T cells. CD4 T cells were
stimulated with plate-bound anti-CD3/anti-CD28 for 2 days and
rested for 1 day. Following this, they were surface stained with
anti-LAP/TGF-b mAbs using PE-labeled anti-mouse IgG1 (for
IgG1 subtype clones) or anti-mouse Igk secondary antibody (for
non-IgG1 clones), then fixed and intracellularly stained with anti-
Foxp3-Alexa Fluor647. Of the 36 potential anti-LAP/TGF-b
candidate clones, 31 clones surface stained Foxp3
+ cells. Three
representative clones (TW7-16B4, TW7-20B9, and TW7-28G11)
are shown in Figure 1A and all 36 clones are shown in Figure S6.
It should be noted that 24 of the 26 clones which immunopre-
cipitated Flag-mLAP as described above stained Foxp3
+ CD4 T
cells with a similar pattern. Among them, TW7-16B4 produced
the highest staining signal followed by TW7-20B9. An anti-pro-
TGF-b/latent TGF-b clone, TW7-28G11, also stained Foxp3
+
CD4 T cells (Figure 1A and Figure S6), suggesting that surface
LAP exists as pro-TGF-b and/or latent TGF-b rather than free
LAP without mature TGF-b. Surface LAP staining strongly
correlated with GARP expression (Figure 1B), indicating that
surface LAP on mouse Foxp3
+ CD4 Tregs is also anchored by
GARP as on human FOXP3
+ CD4 Tregs.
For further analysis we selected TW7-16B4 (IgG1, k) and TW7-
20B9 (IgG1, k) as the highest staining anti-LAP clones, and TW7-
28G11 (IgG2b, k) as an anti-pro-TGF-b/latent TGF-b clone.
These clones were used with secondary antibodies or as antibodies
directly labeled with PE or Allophycocyanin (APC). We tested
whether unstimulated CD4 T cells also express surface LAP using
the direct conjugates. We found that freshly prepared mouse
CD4
+25
+ T cells also weakly expressed surface LAP (Figure 2A).
We also investigated the time course of surface LAP expression.
We found that surface LAP expression on Foxp3
+ cells peaked on
days 1 and 2, and then gradually decreased when the cells were
rested (days 3 and 5) (Figure 2B, upper panels). We found that
GARP was co-expressed with LAP in all time points (Figure 2B,
lower panels).
Foxp3-induced surface LAP expression
We then asked whether surface LAP expression is controlled by
Foxp3. We found that retroviral Foxp3 transduction into mouse
CD4
+CD25
2 T cells induced surface LAP (GFP
+ population vs.
GFP
2 population in Figure 3). This result demonstrates that
surface LAP is under control of Foxp3.
TGF-b-induced surface LAP expression
TGF-b converts Foxp3
2 CD4 T cells into induced Foxp3
+
Tregs (iTregs) [1]. To determine whether iTregs also express
surface LAP, we stimulated mouse CD4
+CD25
2 T cells in the
presence or absence of recombinant TGF-b and checked for
surface LAP expression. As expected ,25% of CD4
+CD25
- T
cells were converted to Foxp3
+ iTregs in presence of TGF-b
(Figure 4A). We found that these iTregs expressed surface LAP.
Interestingly, the Foxp3
2-remaining cells also became surface
LAP
+ cells following culture in the presence of TGF-b. GARP
expression correlated with surface LAP expression on both Foxp3
+
cells and Foxp3
2 cells (Figure 4B), suggesting that surface LAP is
GARP-dependent not only on natural Tregs and iTregs cells but
also on non-Tregs.
It is possible that surface LAP expression on natural Foxp3
+
Tregs might also be maintained by TGF-b produced by Tregs
themselves. We found, however, that the ALK5 inhibitor or anti-
TGF-b 1D11 did not affect surface LAP expression or GARP
expression on Foxp3
+ Tregs (Figures S7 and S8). Thus, these




The existence and function of surface LAP on Tregs has been a
matter of debate. Contrary to the first report by Nakamura et al.
[3], Shevach’s group questioned the function of TGF-b in Treg-
mediated suppression [13], and their staining of mouse T cells was
quite faint, if at all present [14]. As a part of our investigation of
TGF-b, we found that the anti-human LAP mAb 27232 used by
Nakamura et al. does not cross-react with mouse LAP (Figure S1).
In this report, we raised anti-mouse LAP mAbs by immunization
of TGF-b
2/2 mice and revisited the existence of surface LAP on
mouse CD4 T cells. We found that anti-mouse LAP mAbs stained
majority of Foxp3
+ Tregs, but not Foxp3
2 T cells after activation
(Figure 1A). Fresh CD4
+CD25
+ T cells also expressed surface LAP
at a weak level (Figure 2A). Thus our results establish that mouse
Foxp3
+ Tregs do express surface LAP. It should be mentioned,
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b has a functional contribution to Treg-mediated suppression.
Using the anti-LAP mAb 27232 [7,8] it was recently reported
that human FOXP3
+ Tregs express surface LAP and that the
surface LAP is anchored by GARP [8,9]. It appears that this is also
the case with mouse CD4 T cells since GARP expression strongly
correlated with surface LAP expression (Figure 1B and Figure 2B).
We recently reported the occurrence of GARP-independent,
GRP78-associated surface LAP on TGFB1-transduced cells [6]. It
is unknown at this time whether GARP-independent surface LAP
also can be seen on T cells.
In humans, TGF-b-induced FOXP3
+ CD4 T cells do not
express surface LAP or GARP [8]. On the contrary, in mice, not
only did TGF-b-induced Foxp3
+ CD4 T cells express surface LAP
Figure 1. Surface LAP/TGF-b expression on mouse activated CD4 T cells. (A) BALB/c CD4 T cells were stimulated with plate-bound anti-CD3/
anti-CD28 for 2 days and rested for 1 day. The cells were surface stained with anti-LAP mAbs using PE-labeled secondary antibodies, then
intracellularly stained with anti-Foxp3-Alexa Fluor647. Staining with representative clones, anti-LAP mAbs TW7-16B4 and TW7-20B9, and anti-latent
TGF-b/pro-TGF-b mAb TW7-28G11, are shown. (B) Activated BALB/c CD4 T cells were stained with anti-LAP TW7-20B9 (surface) and anti-Foxp3
(intracellular) (left), with anti-GARP (surface) and anti-Foxp3 (intracellular), or anti-LAP TW7-20B9 (surface) and GARP (surface) (right).
doi:10.1371/journal.pone.0015523.g001
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+CD25
2 T cells that did not
become Foxp3
+ CD4 T cells also expressed surface LAP and
GARP (Figure 4B). Some Foxp3
2 CD4 T cells also expressed
surface LAP/TGF-b without exogenous of TGF-b. We do not
know whether this LAP/TGF-b expression was induced by TGF-
b in an autocrine fashion or occurred independent of TGF-b.
However, TGF-b signaling seems not absolutely required for
surface LAP expression since natural Foxp3
+ Tregs maintained
surface LAP expression even when TGF-b signaling was blocked
(Figure S7). Thus, surface LAP expression may be controlled
independently by Foxp3 and TGF-b signaling.
In summary, we raised anti-mouse LAP mAbs and revisited
surface LAP expression on mouse CD4 T cells. We found that
Foxp3
+ Tregs expressed surface LAP and that surface LAP is
induced by forced expression of Foxp3 or by TGF-b irrespective of
Foxp3 induction. Furthermore, surface LAP expression strongly
correlated with GARP, suggesting that surface LAP is GARP-
mediated. These newly described anti-mouse LAP mAbs will
Figure 2. Surface LAP/TGF-b expression on mouse unstimulated CD4 T cells and time course analysis. (A) Freshly prepared BALB/c CD4
T cells were surface stained with PE-conjugated anti-LAP/TGF-b mAbs (TW7-16B4, TW7-20B9, or TW7-28G11), anti-CD25-FITC, anti-CD4-APC, and 7-
AAD. CD4
+7-AAD
2 cells were gated. (B) BALB/c CD4 T cells were stimulated with plate-bound anti-CD3/anti-CD28 for two days, and then split in 10%
FBS-IMDM containing 100 U/ml IL-2. The cells were surface stained with PE-conjugated anti-LAP TW7-20B9 followed by anti-Foxp3-Alexa Fluor647
(intracellular staining) (upper panels), or with APC-conjugated anti-LAP TW7-20B9 and GARP-PE (lower panels).
doi:10.1371/journal.pone.0015523.g002
Surface LAP on Murine CD4 T cells
PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e15523provide a useful tool for functional analysis of T cells that express
LAP on their surface.
Materials and Methods
Generation of anti-mouse LAP mAbs (TW7 series)
Mice were housed in a pathogen-free environment and the
animal protocols were approved according to the guidelines of the
Committee on Animals of Harvard Medical School (Protocol
No. 02683). TGF-b
2/2 mice [10] were injected i.p. with 20 mg
galectin-1 (Sigma-Aldrich) [12] every other day starting at 7 day
after birth to prevent the fatal autoimmunity seen in TGF-b
2/2
mice [11]. Mouse Tgfb1-transduced P3U1 (P3U1-muTGF-b) cells
(clone #11) were injected i.p. at 1-4610
6 cells (in 10–25 mlP B S )
every other day 5 times starting at 8 days after birth. At age 22 days,
the spleen cells were fused with P3U1 myeloma cells, and the
hybridoma cells were plated in methylcellulose medium (ClonaCell-
HY, Stemcell Technologies). Screening was conducted by surface
staining of P3U1-muTGF-b cells by FACS. Anti-mouse LAP
specificity was confirmed by immunoprecipitation of recombinant
Flag-tagged mouse LAP (lacking C-terminal mature TGF-b
sequence) (Flag-mLAP) [15], immunoprecipitation of pro-TGF-b
and latent TGF-b, staining recombinant human latent TGF-b
(R&D Systems)-coated polystyrene beads, and/or staining recom-
binant human TGF-b (R&D Systems) coated polystyrene beads.
Other antibodies and reagents
Anti-human LAP mAb clone 27232, anti-TGF-b mAb clone
9016, and biotinylated goat anti-LAP (BAF246) were obtained
from R&D Systems. Anti-mouse CD3 (145-2C11), anti-mouse
CD28 (37.51), Allophycocyanin (APC)-labeled goat anti-mouse
Ig, PE- or APC-labeled anti-mouse IgG1 (A85-1), and PE-labeled
anti-mouse Igk (187.1) were from BD Biosciences. PE-labeled
anti-mouse GARP (YGIC86), and Alexa Fluor647-labeled anti-
Foxp3 (FJK-16s) were from eBioscience. Alexa Fluor488-labeled
anti-Foxp3 (150D) was from Biolegend. TGF-b receptor I kinase
inhibitor (ALK5 inhibitor II) was from EMD/Calbiochem. Anti-
Flag mAb (M2) was from Sigma-Aldrich. (caga)12-MLP-Luc
TGF-b reporter plasmid [16,17] was kindly provided by Dr. D.
Vivien (the Universite’ de Caen, Daix, France). Mv1Lu cells
(ATCC) were stably transfected with (caga)12-MLP-Luc plasmid
and used for testing dose-response of ALK5 inhibitor II in TGF-b
bioassay.
CD4 T cell stimulation and FACS staining
CD4 T cells were separated from BALB/c mice (The Jackson
Laboratories) or C57BL/6 background Foxp3-GFP knock-in
(Foxp3-KI) mice [18] using MACS CD4 purification kit (Miltenyi
Biotec). When CD4
+CD25
2 T cells were prepared, biotinylated
anti-CD25 antibody was additionally mixed to the MCAS
antibody cocktail. T cells were stimulated with plate-bound anti-
CD3 and anti-CD28 for 2 days. The cells were split into non-
coated wells and rested for 1 day, then stained by FACS. Surface
LAP staining was conducted by either PE- or APC-directly
conjugated anti-mouse LAP mAbs, or unconjugated anti-mouse
LAP mAbs followed by PE- or APC-conjugated goat anti-mouse
Ig, monoclonal anti-mouse IgG1 or monoclonal anti-mouse Igk
secondary antibody. Intracellular Foxp3 staining was done with
Alexa Fluor647- or Alexa Fluor488-labeled anti-Foxp3 using
Foxp3 Staining Buffer Set (eBioscience).
Retroviral transduction
Retroviral vector pMCs-IRES-GFP [19], ecotropic retroviral
packaging cell line Plat-E [20] were kindly provided by Dr.
Kitamura (Tokyo Univ., Tokyo, Japan). Foxp3 was cloned into
pMCs-IRES-GFP vector, and the retroviral supernatant was
produced by Plat-E. Mouse CD4
+25
2 T cells from BALB/c
mice pre-activated with plate-bound anti-CD3 and anti-CD28
for 30 hrs were infected with Foxp3 ecotropic retrovirus by
centrifugation at 3,000 rpm for 1 hr. 1 day after infection, the
cells were split onto a non-coated wells, and rested. The
transduced cells were re-stimulated with plate-bound anti-
CD3/anti-CD28 for 14 hrs, rested for 2 days, and surface
stained with anti-LAP mAbs and then intracellularly with anti-
Foxp3.
Figure 3. Induction of surface LAP by Foxp3 transduction. BALB/c CD4
+CD25
2 T cells were stimulated with plate-bound anti-CD3/anti-CD28
and retrovirally transduced with pMCs-Foxp3-IRES-GFP vector. The cells were re-stimulated with plate-bound anti-CD3/anti-CD28 for 14 hrs and
transferred to uncoated wells. 2 days after re-stimulation, the cells were stained with anti-LAP TW7-16B4 or TW7-20B9 using anti-mouse IgG1-APC
secondary antibody.
doi:10.1371/journal.pone.0015523.g003
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PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e15523Figure 4. Induction of surface LAP by TGF-b. (A) BALB/c CD4
+CD25
2 T cells were stimulated with plate-bound anti-CD3/anti-CD28 without
(upper panels) or with 10 ng/ml recombinant TGF-b (lower panels) for 2 days and rested for 2 days. The cells were surface stained with anti-LAP TW7-
16B4 or TW7-20B9, or anti-latent TGF-b/pro-TGF-b TW7-28G11 using goat anti-mouse Ig-PE secondary antibody, then fixed, and intracellularly stained
Surface LAP on Murine CD4 T cells
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Figure S1 Negative staining of mouse TGF-b-transduced
cells with anti-human LAP mAb 27232. Non-transduced
P3U1 cells (green), human TGF-b gene (TGFB1)-transduced
P3U1 cells (clone #32) (blue), or mouse TGF-b gene (Tgfb1)-
transduced P3U1 (clone #11) cells (red) were surface stained with
anti-TGF-b mAb 9016 (left) or with anti-human LAP mAb 27232
(right). Note that mouse TGF-b-transduced P3U1 cells were later
found positive with anti-mouse LAP mAbs as shown in Figure S2.
(PDF)
Figure S2 Staining of mouse TGF-b-transduced P3U1
cells with TW7 anti-LAP/TGF-b candidate clones. Mouse
TGF-b-transduced P3U1 (clone #11) cells (GFP
+) mixed with
non-transduced P3U1 cells (GFP(
-)) were surface stained with
culture supernatants of anti-LAP/TGF-b candidate clones (TW7
series) using goat anti-mouse Ig-APC after Fc receptor blocking.
Immunoglobulin subtypes are also shown in the figures. Clones
identified as anti-LAP in Fig. 3 are underlined.
(PDF)
Figure S3 Immunoprecipitation of Flag-tagged mouse
LAP with TW7 anti-LAP/TGF-b candidate clones. Culture
supernatant of P3U1 cells transduced with retroviral pMCs vector
carrying Flag-tagged mouse LAP lacking TGF-b sequence (Flag-
mLAP) was immunoprecipitated with anti-LAP/TGF-b candidate
clones using anti-mosue IgG BioMag Plus (Polysciences). The
immunoprecipitated samples were run on SDS-PAGE under
reducing conditions and blotted with anti-Flag mAb M2. Ig H
chain and Ig L chain were detected at 55 kDa and at 25 kDa,
respectively, and Flag-mLAP migrated at 43 kDa. Clones that
immunoprecipitaed Flag-mLAP were marked under the clone
numbers. C, MOPC21 IgG1 control; 1, TW7-1C12 (IgG1); 2,
TW7-3G11 (IgM); 3, TW7-4G7 (IgG1); 4, TW7-5A1 (IgG1); 5,
TW7-5B2 (IgG1); 6, TW7-5B5 (IgG1); 7, TW7-5D4 (IgG1); 8,
TW7-5F5 (IgG1); 9, TW7-5G10 (IgG1); 10, TW7-6B3 (IgG1); 11,
TW7-7C7 (IgG1); 12, TW7-7G7 (IgG1); 13, TW7-7H4 (IgG1); 14,
TW7-8C11 (IgG1); 15, TW7-10C10 (IgG1); 16, TW7-11G5
(IgG1); 17, TW7-12E2 (IgG1); 18, TW7-13C5 (IgG1); 19, TW7-
13C8 (IgG1); 20, TW7-13D7 (IgG1); 21, TW7-13E12 (IgG1); 22,
TW7-16A2 (IgG1); 23, TW7-16B4 (IgG1); 24, TW7-17G8 (IgM);
25, TW7-18C4 (IgG2a or 2b); 26, TW7-18C9 (IgG2a or 2b); 27,
TW7-20B9 (IgG1); 28, TW7-22F7 (IgG1); 29, TW7-22F9 (IgG2a
or 2b); 30, TW7-22H5 (IgG1); 31, TW7-23D12 (IgG1); 32, TW7-
24B11 (IgG1); 33, TW7-24E3 (IgM); 34, TW7-24G5 (IgG1); 35,
TW7-26E10 (IgM); 36, TW7-28G11 (IgG2b).
(PDF)
Figure S4 Characterization of TW7-28G11 clone. (A)
Recombinant human LAP- (left), human latent TGF-b- (middle),
or human active TGF-b- (right) coated polystyrene beads were
stained with TW7-28G11 mAb using goat anti-mouse Ig-APC. (B)
Culture supernatant of Flag-mLAP-transduced P3U1 cells with/
without exogenously added recombinant human TGF-b was
immunoprecipitated with TW7-28G11 or control Ab. The
samples were run on SDS-PAGE under reducing conditions and
blotted with anti-Flag M2 antibody.
(PDF)
Figure S5 Western blotting and immunoprecipitation of
LAP/TGF-b by TW7 mAbs. (A) Culture supernatant of P3U1-
muTGF-b (clone #11) cells (lane 1), or immunoprecipitated
samples from P3U1-muTGF-b culture supernatant with TW7-
7H4 (lane 2), TW7-16B4 (lane 3), TW7-20B9 (lane 4), TW7-22F7
(lane 5), TW7-28G11 (lane 6), or or IgG1 control MOPC21 (lane
7) were run on SDS-PAGE under non-reducing conditions, and
blotted with biotinylated goat anti-LAP Ab. (B) Culture superna-
tant of P3U1-muTGF-b (clone #11) cells were run on SDS-PAGE
under non-reducing conditions and blotted with TW7-16B4 (lane
1), TW7-20B9 (lane 2), TW7-28G11 (lane 3), or biotinylated goat
anti-LAP (lane 4).
(PDF)
Figure S6 Staining of pre-activated mouse CD4 T cells
with TW7 anti-LAP/TGF-b mAb series. BALB/c CD4 T
cells were stimulated with plate-bound anti-CD3/anti-CD28 for 2
days and rested 1 day. The cells were surface stained with TW7
anti-LAP/TGF-b mAbs using PE-labeled anti-mouse IgG1 or
anti-mouse Igk secondary antibodies, then intracellularly stained
with anti-Foxp3-Alexa Fluor647 as Figure 2A. Staining with all 36
TW7 clones was shown.
(PDF)
Figure S7 Surface LAP expression under TGF-b block-
ing conditions. B6 background Foxp3-GFP knock-in CD4 T
cells were stimulated with plate-bound anti-CD3/anti-CD28 in
presence of 10 ng/ml recombinant human TGF-b,1mM ALK5
inhibitor II (Figure S8), or 50 mg/ml anti-TGF-b mAb 1D11 for 2
days, and rested for 1 day. The cells were stained with anti-LAP
TW7-16B4 using anti-mouse IgG1-APC secondary antibody and
anti-GARP-PE. The quadrants were set by isotype control
staining.
(PDF)
Figure S8 Dose response curve of ALK5 inhibitor II. (A)
Mv1Lu cells stably transfected with (caga)12-MLP-Luc vector were
cultured in the presence of recombinant human TGF-b for 8 hrs,
and luciferase was measured. (B) Mv1Lu-(caga)12-MLP-Luc cells
were cultured in presence of 100 pg/ml recombinant human
TGF-b with various concentrations of ALK5 inhibitor II for 8 hrs,
and luciferease was measured.
(PDF)
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